BOSTON, Sept.19, 2019
/PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI),
a clinical stage biopharmaceutical company dedicated to the
discovery and development of groundbreaking therapies to treat
cystic fibrosis (CF) and other diseases caused by dysfunctional
protein processing, today announced that Proteostasis management
will present at the UK Cystic Fibrosis Conference (UKCFC) on
September 26-27, 2019 at the Kia Oval
in Kennington, London,
England.
Details for the presentation are as follows:
Title: Access and the Unmet Need: Novel CFTR
Modulator Combinations are Coming
Presenter: Marija Zecevic, Ph.D., Chief Commercial
Officer
Session Title: Development of new therapies for cystic
fibrosis
Date and time: Thursday, September 26, 2019 from
10:40-11:10 a.m. BST
Location: Kia Oval
A live audio webcast of the UKCFC presentation will be available
on the Investor Events page in the Investors & Media section of
the Company's website, www.proteostasis.com. A replay of the
webcast will be available on the Company's website following the
presentation.
For more information on this meeting, visit:
https://www.cysticfibrosis.org.uk/the-work-we-do/conference-and-meetings/ukcfc
About Proteostasis Therapeutics, Inc.
Proteostasis Therapeutics, Inc. is a clinical stage
biopharmaceutical company developing small molecule therapeutics to
treat cystic fibrosis and other diseases caused by dysfunctional
protein processing. Headquartered in Boston, MA,
the Proteostasis Therapeutics team focuses on identifying
therapies that restore protein function. For more information,
visit www.proteostasis.com.
Safe Harbor
To the extent that statements in this release are not historical
facts, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Words such as "aim," "may," "will," "expect,"
"anticipate," "estimate," "intend," and similar expressions (as
well as other words or expressions referencing future events,
conditions or circumstances) are intended to identify
forward-looking statements. Examples of forward-looking statements
made in this release include, without limitation, statements
regarding the expected presentation at an upcoming
conference. Forward-looking statements made in this release
involve substantial risks and uncertainties that could cause actual
results to differ materially from those expressed or implied by the
forward-looking statements, and we, therefore cannot assure you
that our plans, intentions, expectations or strategies will be
attained or achieved. Such risks and uncertainties include, without
limitation, the potential of our proprietary combination therapies
for the treatment of CF, the potential benefit of our proprietary
combination therapies to patients, expected timing of patient
enrollment in, data from, the completion of, our clinical studies
and cohorts for our clinical programs, including our planned Phase
2 program and initiation of a pivotal study, the possibility final
or future results from our drug candidate trials (including,
without limitation, longer duration studies) do not achieve
positive results or are materially and negatively different from or
not indicative of the preliminary results reported by the Company
(noting that these results are based on a small number of patients
and small data set), uncertainties inherent in the execution and
completion of clinical trials (including, without limitation, the
possibility that FDA or other regulatory agency comments delay,
change or do not permit trial commencement, or intended label, or
the FDA or other regulatory agency requires us to run cohorts
sequentially or conduct additional cohorts or pre-clinical or
clinical studies), in the enrollment of CF patients in our clinical
trials in a competitive clinical environment, in the timing of
availability of trial data, in the results of the clinical trials,
in possible adverse events from our trials, in the actions of
regulatory agencies, in the endorsement, if any, by therapeutic
development arms of CF patient advocacy groups (and the maintenance
thereof), in the commercialization and acceptance of new therapies,
and those set forth in our Annual Report on Form 10-K for the year
ended December 31, 2018, our
Quarterly Report on Form 10-Q for the quarter ended June 30, 2019 and our other SEC filings. We
assume no obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
CONTACTS:
Investors:
David Pitts
/ Claudia Styslinger
Argot Partners
212.600.1902
david@argotpartners.com / claudia@argotpartners.com
Media:
David Rosen
Argot Partners
212.600.1902
david.rosen@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/proteostasis-therapeutics-announces-presentation-at-the-uk-cystic-fibrosis-conference-300922010.html
SOURCE Proteostasis Therapeutics, Inc.